An observational study in Multiple Sclerosis and Urinary Incontinence (UI), sponsored by Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization. Recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 30 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-03-24.
Sponsored by Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 309 studies in Multiple Sclerosis with a site in Turkey — 60 open to participants now, 79 under way, 10 of them phase 3. Multiple Sclerosis · Turkey.
Among the 309 studies in Multiple Sclerosis with a site in Turkey, this one is the 71st largest by planned enrollment of the 103 observational ones that give a count, is one of 44 that started in 2026, is one of 103 observational ones, reaches primary completion later than 50 of the 78 other live ones, and was the 273rd registered.
3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →60 of the 309 studies in Multiple Sclerosis with a site in Turkey are open now. Recruiting first, the newest first:
Yuzuncu Yil University · Sites in Turkey
Ages 18–65
Suleyman Demirel University · Sites in Turkey
Ages 18–65
Hacettepe University · Sites in Turkey
Ages 18–65
Istanbul University - Cerrahpasa · Sites in Turkey
Ages 18–65
Kutahya Health Sciences University · Sites in Turkey
Ages 18+
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.
This study: 30 Years to 50 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
309 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 44 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 47 is below the median of 100 across 972 observational studies indexed under Multiple Sclerosis.
Median enrollment 40 across the 206 interventional studies, 60 across the 103 observational. Of the 205 that completed or were terminated, 37 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
52 of 309 have an industry lead sponsor. The 10 most frequent:
Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization is the lead sponsor of 87 studies on the registry; 15 are open to participants now.
Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization has 3 studies filed under Multiple Sclerosis — fewer than ten, so there is no comparison to draw.
18 of the studies in Multiple Sclerosis with a site in Turkey that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06141473Phase 3SanofiEfficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis | 2027-05-06 |
| NCT07137624Hacettepe UniversityMotor Imagery and Action Observation for Gait Function in MS | 2026-11 |
| NCT07571304Istanbul University - CerrahpasaDual-Task Training in Pediatric Multiple Sclerosis | 2026-12-01 |
| NCT07842731Atılım UniversityInvestigation of the Prevalence of Sarcopenia and Dynapenia According to Disease Stage in Patients With Multiple Sclerosis and Evaluation of the Relationship Between Sarcopenia Severity and Clinical and Functional Parameters | 2026-12-10 |
| NCT06777134Berivan Beril KılıçRelationship Between Pelvic Floor Dysfunctions and Lower Limb Strength and Activation in MS Patients | 2026-12-10 |
Add all 18 to your calendar (.ics) → With an account.
Among the 309 studies in Multiple Sclerosis with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to investigate the relationship between urinary incontinence severity and surface electromyography (EMG) findings in women with multiple sclerosis. It will also examine the association of urinary incontinence with disability, quality of life, physical activity, and fatigue.
This study investigates the relationship between urinary incontinence (UI) severity and pelvic floor muscle activity in women with multiple sclerosis (MS). UI is common in MS and negatively affects quality of life, physical activity, and social participation. The study also explores how UI severity is associated with disability, fatigue, and overall quality of life.
Participants' demographic and clinical information, including age, disease duration, MS type, and disability level (measured by the Expanded Disability Status Scale, EDSS), will be recorded. Standardized questionnaires will assess urinary symptoms, their impact on daily life, physical activity, and fatigue. Pelvic floor muscle activity will be evaluated using surface electromyography (EMG) with biofeedback, conducted by trained physiotherapists.
The study will be conducted at the Pelvic Floor Health Center and is planned as a cross-sectional study. All assessments, including questionnaires and EMG measurements, are expected to take approximately 45 minutes per participant. Findings from this study aim to improve understanding of UI in women with MS and guide future interventions.
The study will include female patients with multiple sclerosis (MS) aged 30-50 years, diagnosed according to the 2017 revised McDonald criteria, who experience urinary incontinence symptoms according to the International Continence Society (ICS) definition and have an EDSS score below 6.5. Participants must be able to communicate effectively. Patients who do not provide consent, have had a medication change within the last 6 months, are pregnant, have had a vaginal or cesarean delivery within the last 6 months, have pelvic organ prolapse, or have a urinary tract infection will be excluded.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of multiple sclerosis (MS) according to the 2017 revised McDonald criteria.
Female patients aged 30-50 years (age range with higher prevalence of urinary incontinence in MS).
Experiencing urinary incontinence (UI) symptoms according to the International Continence Society (ICS) definition.
EDSS (Expanded Disability Status Scale) score below 6.5.
Patients with no communication difficulties. -
Exclusion Criteria:
MS patients who do not provide consent to participate in the study.
MS patients who have had a medication change within the last 6 months.
Pregnant MS patients.
History of vaginal or cesarean delivery within the last 6 months.
Pelvic organ prolapse.
Urinary tract infection
-
Participants will be observed for EMG activity, fatigue, physical activity, and urinary incontinence symptoms.
Pelvic floor muscle activity with surface EMG
Evaluated using biofeedback-assisted surface EMG. Metrics recorded include mean EMG activity during contraction and rest phases, standard deviation of EMG activity, peak and minimum EMG values, contraction onset, and relaxation times
Time frame: baseline
International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF)
Assesses severity and impact of urinary incontinence
Time frame: baseline
Incontinence Impact Questionnaire (IIQ-7)
Evaluates the effect of urinary incontinence on quality of life
Time frame: baseline
International Physical Activity Questionnaire (IPAQ)
Assesses participants' physical activity levels
Time frame: baseline
Fatigue Severity Scale (FSS)
Measures severity of fatigue experienced by participants
Time frame: baseline
Plan to share: No — Individual participant data (IPD) from this study will not be shared with other researchers.
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Sep 2026, 6 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization